Neurobo Pharmaceuticals Inc (NRBO)

NASDAQ
Currency in USD
Disclaimer
0.4906
+0.0016(+0.33%)
Real-time Data
Day's Range
0.47970.5189
52 wk Range
0.36112.3300
Prev. Close
0.49
Open
0.48
Day's Range
0.4797-0.5189
52 wk Range
0.3611-2.33
Volume
80,082
Average Volume (3m)
59,785
1-Year Change
-68.85%
Shares Outstanding
38,812,518
Fair Value
Unlock
Dividends Payment Streak
Unlock
Analysts
Technical
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
6.0000
Upside +1,122.9923%

People Also Watch

3.6332
BFRI
-1.54%
0.255
RSLS
+7.14%
7.250000
SPRC
-1.09%
0.5651
YGMZ
-1.70%
How do you feel today about NRBO?
Vote to see community's results!
or

Neurobo Pharmaceuticals Inc Company Profile

NeuroBo Pharmaceuticals, Inc., a clinical-stage biotechnology company focuses on developing and commercializing novel pharmaceuticals to treat cardiometabolic diseases. It develops DA-1241, a novel G-Protein-Coupled Receptor 119 agonist with development optionality as a standalone and/or combination therapy for both NASH and T2D; and DA-1726, a novel oxyntomodulin analogue functioning as a GLP1R/GCGR dual agonist for the treatment of NASH and obesity. The company also develops ANA001, a proprietary oral niclosamide formulation for the treatment of patients with moderate COVID-19; NB-01 for the treatment of painful diabetic neuropathy; NB-02 to treat the symptoms of cognitive impairment and modify the progression of neurodegenerative diseases associated with the malfunction of tau protein; and Gemcabene for various indications, including COVID-19 in combination with ANA001. NeuroBo Pharmaceuticals, Inc. was incorporated in 2014 and is headquartered in Boston, Massachusetts.